{"id":28164,"date":"2023-02-17T21:46:38","date_gmt":"2023-02-18T02:46:38","guid":{"rendered":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/"},"modified":"2024-05-01T16:28:22","modified_gmt":"2024-05-01T20:28:22","slug":"la-fda-otorga-aprobacion-acelerada-a-filspari-para-el-tratamiento-de-la-nefropatia-por-iga","status":"publish","type":"post","link":"https:\/\/nephcure.org\/es\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/","title":{"rendered":"La FDA otorga la aprobaci\u00f3n acelerada a FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos"},"content":{"rendered":"<p style=\"font-weight: 400;\">Hoy es un d\u00eda incre\u00edblemente prometedor para la comunidad de enfermedades renales raras (RKD): la FDA ha anunciado que <a href=\"https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-fda-accelerated-approval\" target=\"_blank\" rel=\"noopener\">el medicamento FILSPARI (sparsentan)<\/a> Se le ha concedido aprobaci\u00f3n acelerada para el tratamiento de la nefropat\u00eda por IgA en adultos.<\/p>\n<p style=\"font-weight: 400;\">El <a href=\"https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program\">Programa de aprobaci\u00f3n acelerada de la FDA<\/a> permite la aprobaci\u00f3n m\u00e1s temprana de medicamentos que tratan afecciones graves y satisfacen una necesidad m\u00e9dica no cubierta. A FILSPARI se le ha concedido una aprobaci\u00f3n acelerada basada en la reducci\u00f3n de la proteinuria. A\u00fan no se sabe si el f\u00e1rmaco retarda el deterioro de la funci\u00f3n renal en pacientes con NIgA.<\/p>\n<p style=\"font-weight: 400;\">Durante los pr\u00f3ximos meses, Travere Therapeutics, la compa\u00f1\u00eda que desarroll\u00f3 FILSPARI, compartir\u00e1 m\u00e1s informaci\u00f3n sobre este nuevo tratamiento y explicar\u00e1 cu\u00e1ndo y c\u00f3mo quienes necesitan el medicamento pueden acceder a \u00e9l.<\/p>\n<p style=\"font-weight: 400;\">\u201cEste es el momento por el que todos hemos estado trabajando. La aprobaci\u00f3n de FILSPARI por la FDA para la nefropat\u00eda por IgA es monumental para toda la comunidad de enfermedades renales raras. Hoy marca el comienzo de una nueva era para el tratamiento de RKD: es un testimonio del compromiso de la comunidad de investigaci\u00f3n y de Travere con nuestros pacientes\u201d, afirm\u00f3 Josh Tarnoff, director ejecutivo de NephCure.<\/p>\n<p style=\"font-weight: 400;\">\u201cNuestra comunidad colectiva est\u00e1 incre\u00edblemente orgullosa de haber llegado a este punto, pero sabemos que ahora comienza la siguiente fase de nuestro trabajo vital: garantizar que quienes necesitan este medicamento tengan acceso a \u00e9l a tiempo para salvar sus ri\u00f1ones. Hemos esperado tantos a\u00f1os por este tratamiento. La aprobaci\u00f3n de hoy de la FDA proporciona un rayo de esperanza de que es probable que pronto est\u00e9n disponibles m\u00e1s tratamientos nuevos necesarios\u201d.<\/p>\n<p style=\"font-weight: 400;\">La aprobaci\u00f3n continua de FILSPARI puede depender de los datos del estudio PROTECT de fase 3 en curso de Travere. Este estudio eval\u00faa el f\u00e1rmaco en m\u00e1s de 400 pacientes con proteinuria persistente. Despu\u00e9s de 36 semanas de tratamiento, los pacientes que recibieron el f\u00e1rmaco lograron una reducci\u00f3n de casi 50% en la proteinuria.<\/p>\n<p style=\"font-weight: 400;\">Si bien esta es una nueva era para los pacientes con RKD y sus familias, sabemos que todav\u00eda nos queda un largo camino por recorrer. FILSPARI tambi\u00e9n se est\u00e1 estudiando en pacientes con GEFS y podr\u00eda aprobarse para el tratamiento de la GEFS durante el pr\u00f3ximo a\u00f1o. Con m\u00e1s de 60 oportunidades de ensayos cl\u00ednicos para pacientes con RKD, es probable que se aprueben a\u00fan m\u00e1s tratamientos nuevos en un futuro pr\u00f3ximo.<\/p>\n<p style=\"font-weight: 400;\">Lo celebramos hoy, pero sabemos que a\u00fan no hemos cruzado la l\u00ednea de meta. Debemos seguir impulsando la investigaci\u00f3n para poder seguir mejorando los resultados de salud de los pacientes con RKD. Como mencion\u00f3 Josh, ahora nos enfrentamos a un nuevo desaf\u00edo: garantizar que todos los pacientes tengan acceso oportuno y equitativo a estos nuevos y mejores tratamientos.<\/p>\n<p style=\"font-weight: 400;\">Seguimos centrados en nuestra misi\u00f3n de capacitar a las personas con una enfermedad renal rara que derrama prote\u00ednas para que se hagan cargo de su salud, mientras lideramos la revoluci\u00f3n en investigaci\u00f3n, nuevos tratamientos y atenci\u00f3n.<\/p>\n<p style=\"font-weight: 400;\">Le agradecemos su incre\u00edble apoyo que nos ha ayudado a llegar hasta el d\u00eda de hoy y estamos agradecidos por su continua dedicaci\u00f3n a nuestra misi\u00f3n.<\/p>","protected":false},"excerpt":{"rendered":"<p>Hoy es un d\u00eda incre\u00edblemente prometedor para la comunidad de enfermedades renales raras (RKD): la FDA ha anunciado que se ha concedido la aprobaci\u00f3n acelerada al medicamento FILSPARI (sparsentan) para el tratamiento... <a title=\"La FDA otorga la aprobaci\u00f3n acelerada a FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos\" class=\"read-more\" href=\"https:\/\/nephcure.org\/es\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/\" aria-label=\"Leer m\u00e1s sobre La FDA otorga la aprobaci\u00f3n acelerada de FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos\">Leer m\u00e1s<\/a><\/p>","protected":false},"author":222,"featured_media":28165,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[354],"tags":[],"disease-category":[],"resource-type":[260],"treatment-option":[],"hf_cat_post":[],"class_list":["post-28164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news","resource-type-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults - NephCure<\/title>\n<meta name=\"description\" content=\"Today marks an incredibly promising day for the rare kidney disease (RKD) community: the FDA has announced that the drug FILSPARI (sparsentan) has been - Read more about FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults on NephCure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nephcure.org\/es\/la-fda-otorga-aprobacion-acelerada-a-filspari-para-el-tratamiento-de-la-nefropatia-por-iga\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults\" \/>\n<meta property=\"og:description\" content=\"Today marks an incredibly promising day for the rare kidney disease (RKD) community: the FDA has announced that the drug FILSPARI (sparsentan) has been - Read more about FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults on NephCure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nephcure.org\/es\/la-fda-otorga-aprobacion-acelerada-a-filspari-para-el-tratamiento-de-la-nefropatia-por-iga\/\" \/>\n<meta property=\"og:site_name\" content=\"NephCure\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nephcure\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-18T02:46:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-01T20:28:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1890\" \/>\n\t<meta property=\"og:image:height\" content=\"1890\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lauren Eva\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nephcure\" \/>\n<meta name=\"twitter:site\" content=\"@nephcure\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lauren Eva\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/\"},\"author\":{\"name\":\"Lauren Eva\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/a14d37658f18eebfa8f67b57b3f8e0ff\"},\"headline\":\"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults\",\"datePublished\":\"2023-02-18T02:46:38+00:00\",\"dateModified\":\"2024-05-01T20:28:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/\"},\"wordCount\":476,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/\",\"name\":\"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults - NephCure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"datePublished\":\"2023-02-18T02:46:38+00:00\",\"dateModified\":\"2024-05-01T20:28:22+00:00\",\"description\":\"Today marks an incredibly promising day for the rare kidney disease (RKD) community: the FDA has announced that the drug FILSPARI (sparsentan) has been - Read more about FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults on NephCure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"width\":1890,\"height\":1890},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nephcure.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"name\":\"NephCure\",\"description\":\"For Rare Kidney Disease\",\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nephcure.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\",\"name\":\"NephCure\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"width\":512,\"height\":512,\"caption\":\"NephCure\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nephcure\\\/\",\"https:\\\/\\\/x.com\\\/nephcure\",\"https:\\\/\\\/www.instagram.com\\\/nephcure\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nephcure\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/Nephcure\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/a14d37658f18eebfa8f67b57b3f8e0ff\",\"name\":\"Lauren Eva\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"caption\":\"Lauren Eva\"},\"sameAs\":[\"https:\\\/\\\/nephcure.org\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La FDA otorga la aprobaci\u00f3n acelerada a FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos - NephCure","description":"Hoy marca un d\u00eda incre\u00edblemente prometedor para la comunidad de enfermedades renales raras (RKD): la FDA ha anunciado que el medicamento FILSPARI (sparsentan) ha sido - Lea m\u00e1s sobre La FDA otorga la aprobaci\u00f3n acelerada de FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos con NephCure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nephcure.org\/es\/la-fda-otorga-aprobacion-acelerada-a-filspari-para-el-tratamiento-de-la-nefropatia-por-iga\/","og_locale":"es_MX","og_type":"article","og_title":"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults","og_description":"Today marks an incredibly promising day for the rare kidney disease (RKD) community: the FDA has announced that the drug FILSPARI (sparsentan) has been - Read more about FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults on NephCure.","og_url":"https:\/\/nephcure.org\/es\/la-fda-otorga-aprobacion-acelerada-a-filspari-para-el-tratamiento-de-la-nefropatia-por-iga\/","og_site_name":"NephCure","article_publisher":"https:\/\/www.facebook.com\/nephcure\/","article_published_time":"2023-02-18T02:46:38+00:00","article_modified_time":"2024-05-01T20:28:22+00:00","og_image":[{"width":1890,"height":1890,"url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","type":"image\/png"}],"author":"Lauren Eva","twitter_card":"summary_large_image","twitter_creator":"@nephcure","twitter_site":"@nephcure","twitter_misc":{"Escrito por":"Lauren Eva","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#article","isPartOf":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/"},"author":{"name":"Lauren Eva","@id":"https:\/\/nephcure.org\/#\/schema\/person\/a14d37658f18eebfa8f67b57b3f8e0ff"},"headline":"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults","datePublished":"2023-02-18T02:46:38+00:00","dateModified":"2024-05-01T20:28:22+00:00","mainEntityOfPage":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/"},"wordCount":476,"commentCount":0,"publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"image":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","articleSection":["Recent News"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/","url":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/","name":"La FDA otorga la aprobaci\u00f3n acelerada a FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos - NephCure","isPartOf":{"@id":"https:\/\/nephcure.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#primaryimage"},"image":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","datePublished":"2023-02-18T02:46:38+00:00","dateModified":"2024-05-01T20:28:22+00:00","description":"Hoy marca un d\u00eda incre\u00edblemente prometedor para la comunidad de enfermedades renales raras (RKD): la FDA ha anunciado que el medicamento FILSPARI (sparsentan) ha sido - Lea m\u00e1s sobre La FDA otorga la aprobaci\u00f3n acelerada de FILSPARI para el tratamiento de la nefropat\u00eda por IgA en adultos con NephCure.","breadcrumb":{"@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#primaryimage","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","width":1890,"height":1890},{"@type":"BreadcrumbList","@id":"https:\/\/nephcure.org\/fda-grants-filspari-accelerated-approval-for-the-treatment-of-iga-nephropathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nephcure.org\/"},{"@type":"ListItem","position":2,"name":"FDA Grants FILSPARI Accelerated Approval for the Treatment of IgA Nephropathy in Adults"}]},{"@type":"WebSite","@id":"https:\/\/nephcure.org\/#website","url":"https:\/\/nephcure.org\/","name":"NephCure","description":"Para enfermedades renales raras","publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nephcure.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nephcure.org\/#organization","name":"NephCure","url":"https:\/\/nephcure.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","width":512,"height":512,"caption":"NephCure"},"image":{"@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nephcure\/","https:\/\/x.com\/nephcure","https:\/\/www.instagram.com\/nephcure\/","https:\/\/www.linkedin.com\/company\/nephcure\/","https:\/\/www.youtube.com\/user\/Nephcure"]},{"@type":"Person","@id":"https:\/\/nephcure.org\/#\/schema\/person\/a14d37658f18eebfa8f67b57b3f8e0ff","name":"loren eva","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","caption":"Lauren Eva"},"sameAs":["https:\/\/nephcure.org"]}]}},"_links":{"self":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/users\/222"}],"replies":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/comments?post=28164"}],"version-history":[{"count":0,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28164\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media\/28165"}],"wp:attachment":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media?parent=28164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/categories?post=28164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/tags?post=28164"},{"taxonomy":"disease-category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/disease-category?post=28164"},{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/resource-type?post=28164"},{"taxonomy":"treatment-option","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/treatment-option?post=28164"},{"taxonomy":"hf_cat_post","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/hf_cat_post?post=28164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}